Obicetrapib Breaks the CETP Curse: NewAmsterdam’s Strategic European Rollout

NAARDEN, Netherlands and MIAMI – November 04, 2026 – For over two decades, the cholesteryl ester transfer protein (CETP) inhibitor class was the graveyard of pharmaceutical giants. Industry titans poured billions of dollars into compounds designed to manage cholesterol, only to be met with devastating safety signals or underwhelming efficacy. Today, a mid-cap biopharmaceutical company has officially achieved what the titans could not. NewAmsterdam Pharma Company N.V. has reported its third-quarter 2026 financial results, anchored by a watershed moment in cardiovascular medicine: the European Commission’s marketing authorization for Ubeslo and Evlarco, marking the first regulatory approval of a CETP inhibitor anywhere in the world.

The approval transforms NewAmsterdam from a late-stage clinical developer into a commercial-stage entity, triggering immediate milestone payments and setting the stage for a high-stakes European rollout. But the company’s ambitions do not stop at cardiovascular disease. In a strategic maneuver that redefines the asset's potential, NewAmsterdam has simultaneously initiated a Phase 2b trial for obicetrapib in preclinical Alzheimer’s disease, betting that a drug designed for the heart might hold the key to the brain.

Breaking a Decades-Long Pharmaceutical Curse

To understand the magnitude of the European Commission's approval of Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib paired with ezetimibe), one must look at the wreckage of past CETP inhibitors. Pfizer’s torcetrapib was abruptly halted in 2006 after data revealed an increase in cardiovascular events and deaths. Roche’s dalcetrapib and Eli Lilly’s evacetrapib were both abandoned in the early 2010s due to a lack of clinical efficacy. Merck’s anacetrapib managed to demonstrate a cardiovascular benefit in 2017, but the company ultimately shelved the drug due to concerns over its accumulation in adipose tissue and relatively modest efficacy.

NewAmsterdam's obicetrapib appears to have threaded the needle, demonstrating potent low-density lipoprotein cholesterol (LDL-C) reductions of up to 40% as a monotherapy and approximately 50% when combined with ezetimibe, all while maintaining a tolerability profile comparable to a placebo.

“The third quarter was marked by significant progress across our regulatory and clinical priorities, including the first regulatory approval of obicetrapib worldwide and the initiation of the SPINOZA Phase 2b trial in preclinical Alzheimer’s disease,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma.

While the regulatory nod in Europe is a historic victory, the ultimate test of obicetrapib’s commercial dominance lies in the ongoing PREVAIL Phase 3 cardiovascular outcomes trial (CVOT). Having fully enrolled over 9,500 patients, NewAmsterdam anticipates reaching the predefined event number for an interim analysis in the fourth quarter of 2026, with results expected in the first quarter of 2027. If PREVAIL demonstrates a definitive reduction in major adverse cardiovascular events (MACE), obicetrapib will transition from a novel lipid-lowering alternative to a foundational pillar of cardiovascular care.

The Menarini Partnership and European Commercial Realities

Securing regulatory approval is only half the battle; monetizing it requires flawless execution. To navigate the fragmented and notoriously complex European market, NewAmsterdam has entrusted exclusive commercialization rights to the Menarini Group, an Italy-based pharmaceutical heavyweight with a distribution network spanning 140 countries.

The economics of the partnership are highly favorable for NewAmsterdam. The company is entitled to tiered royalties on net sales ranging from the low double-digits to the mid-twenties, alongside up to €817 million in potential clinical, regulatory, and commercial milestones. The recent European Commission approval immediately triggered milestone payments in the mid-teens of millions of euros, providing a non-dilutive capital injection that boosted NewAmsterdam's Q3 2026 revenue to $19.2 million—a stark contrast to the $300,000 reported in the same period last year.

Menarini plans to launch the drug in Germany by the end of 2026, leveraging its Berlin-Chemie subsidiary, followed by a United Kingdom rollout in 2027. However, the European pricing landscape is treacherous. In Germany, the Federal Joint Committee (G-BA) will rigorously assess the drug's added medical benefit to determine its reimbursement price. The situation in the UK is even more demanding. In September 2026, the National Institute for Health and Care Excellence (NICE) provisionally recommended against reimbursing Ubeslo and Evlarco, citing uncertainties in clinical and economic evidence.

This provisional pushback from NICE is a stark reminder that clinical innovation must be matched by airtight health economic data. Menarini and NewAmsterdam will need to aggressively negotiate and present compelling real-world value propositions to ensure the drug reaches the millions of European patients failing to meet their LDL-C targets on standard statin therapies.

An Audacious Pivot: From Heart Disease to Alzheimer’s

While the cardiovascular market represents a multi-billion-dollar opportunity, NewAmsterdam is executing a strategic realignment that could exponentially increase its valuation. In September 2026, the company dosed the first participant in the SPINOZA Phase 2b clinical trial, evaluating obicetrapib in approximately 400 individuals with preclinical Alzheimer’s disease.

This neurodegenerative pivot is not a shot in the dark; it is a calculated risk born from deep biomarker analysis. During the Phase 3 BROADWAY cardiovascular trial, researchers conducted a pre-specified analysis of Alzheimer’s biomarkers in patients carrying the ApoE4 gene—a major genetic risk factor for the disease. The data revealed statistically significant reductions in plasma p-tau217, a critical biomarker of Alzheimer’s pathology, over a 12-month period.

The scientific rationale hinges on the growing recognition of lipid metabolism's role in neurodegeneration. By modulating cholesterol and lipoprotein levels, CETP inhibitors may influence brain lipid homeostasis, potentially mitigating the toxic accumulation of amyloid and tau proteins. If the SPINOZA trial validates this hypothesis, NewAmsterdam will have effectively repurposed a de-risked cardiovascular asset into a highly coveted neurodegenerative therapy, completely altering the company's total addressable market and making it a prime acquisition target for larger pharmaceutical players desperate for Alzheimer's pipeline assets.

Financial Fortress and the Road to 2027

Corporate maneuvers of this scale require immense capital, and NewAmsterdam’s balance sheet reflects a company preparing for a prolonged campaign. As of September 30, 2026, the company reported cash, cash equivalents, and marketable securities totaling $643.1 million.

While research and development expenses climbed to $39.4 million for the quarter—driven by the expansive clinical program and personnel costs—the company’s net loss narrowed significantly to $17.4 million, down from $72.0 million in Q3 2025. This financial efficiency, aided by the Menarini milestone revenues and favorable fair value changes in derivative warrant liabilities, provides NewAmsterdam with a robust runway to weather the expensive commercialization phase and fund its ambitious clinical pipeline.

The next six months will dictate the trajectory of the company for the next decade. Top-line data from the Phase 3 RUBENS trial, evaluating obicetrapib in patients with type 2 diabetes or metabolic syndrome, is expected around year-end. But the true inflection point remains the PREVAIL CVOT interim readout in early 2027.

NewAmsterdam is no longer just a biotech firm trying to bring a drug to market; it is the architect of a major therapeutic resurrection. By breaking the CETP curse in Europe and leveraging its cardiovascular data to pioneer a novel Alzheimer's treatment, the company is demonstrating how astute capital allocation and deep biological insight can redefine the boundaries of modern medicine. The industry is watching closely, as the success of these dual maneuvers will undoubtedly reshape the competitive landscape of both cardiometabolic and neurodegenerative care.